Stephen Kajencki, MD
Family Medicine · Mansfield, MANPI 1073521753
Payments from drug & device makers
Across 140 payments — averaging $18.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$531
- AstraZeneca$335
- Pfizer$267
- Johnson & Johnson$238
- Lilly USA, LLC$215
- GSK$200
- plus $860 from 22 others
What the payments were for
- Food & beverage$2,646100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 29 | $531 |
| AstraZeneca | 19 | $335 |
| Pfizer | 18 | $267 |
| Johnson & Johnson(2 entities) | 13 | $238 |
| Lilly USA, LLC | 9 | $215 |
| GSK | 9 | $200 |
| Boehringer Ingelheim | 8 | $172 |
| Abbott | 7 | $154 |
| AbbVie | 4 | $83 |
| Hologic Sales And Service, LLC | 3 | $54 |
| Lifescan, Inc. | 2 | $45 |
| Novartis | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Verona Pharma, Inc. | 1 | $30 |
| Bayer | 1 | $25 |
| Nestle Healthcare Nutrition Inc. | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Indivior Inc. | 1 | $20 |
| Corcept Therapeutics | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Cranial Technologies, Inc | 1 | $17 |
| Lucid Diagnostics Inc. | 1 | $16 |
| Kaleo, Inc. | 1 | $15 |
| Merck | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Seqirus USA Inc | 1 | $13 |
| Genentech USA, Inc. | 1 | $11 |
How this compares
$2,646 in reported general payments places this provider in the 90th percentile of 1,049 family medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 130 | $107,427 |
| OxycontinOxycodone Hcl | 60 | $93,284 |
| JardianceEmpagliflozin | 79 | $81,466 |
| XareltoRivaroxaban | 45 | $48,739 |
| TrulicityDulaglutide | 37 | $47,550 |
| JanuviaSitagliptin Phosphate | 18 | $25,355 |
| RexultiBrexpiprazole | 13 | $18,410 |
| OzempicSemaglutide | 13 | $17,430 |
| VascepaIcosapent Ethyl | 18 | $9,040 |
| DexilantDexlansoprazole | 12 | $8,515 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $6,621 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $5,991 |
| Atorvastatin Calcium | 458 | $5,134 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $5,003 |
| Testosterone | 52 | $4,822 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $267 | $107,427130 claims |
| Boehringer IngelheimJardiance | $172 | $81,46679 claims |
| Johnson & JohnsonXarelto | $238 | $48,73945 claims |
| Lilly USA, LLCTrulicity | $215 | $47,55037 claims |
| MerckJanuvia, Janumet Xr | $15 | $31,97630 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $39 | $18,41013 claims |
| Novo NordiskOzempic | $531 | $17,43013 claims |
| AstraZenecaSymbicort | $335 | $5,99123 claims |
| AbbVieSynthroid | $83 | $1,83626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,049 family medicine providers in Massachusetts.
Other family medicine in Mansfield
- Sonal PatelMansfield$6K
- Robert BeckWestford$2.1M
- Katherine Gergen BarnettBoston$226K
- Peter O'DwyerBoston$163K
- Kelly LannuttiWeymouth$122K
- Larry CulpepperBoston$109K
- Jennifer WeylerWorcester$105K
- Megan McCoyFramingham$75K
- Kristina GraceyWorcester$73K
- Suzanne MitchellBoston$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.